...
首页> 外文期刊>Biochemical and Biophysical Research Communications >TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats
【24h】

TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats

机译:TRPV1激活参与缺血再灌注损伤大鼠远端肢体缺血后处理的心脏保护

获取原文
获取原文并翻译 | 示例
           

摘要

Limb remote ischemic postconditioning (RIPostC) has been proved to be a safe and effective measurement of cardioprotection against ischemia-reperfusion injury. But what bridges the remote organ insult and the cardioprotective effect in heart remains to be elucidated. This study aimed to found that whether TRPV1 may mediate the cardioprotective effect from remote organ to heart and the role of CGRP and SP in this process. We found that RIPostC effectively ameliorated cardiac ischemia/reperfusion injury in terms of limiting infarct size, lowering CK and cTnI release and improving cardiac function. In addition, these cardioprotective effects could be significantly abolished by inhibition of either CGRP or SP receptors with corresponding antagonists (CGRP8-37 for CGRP and RP-67580 for SP) injected before reperfusion. Besides, RIPostC resulted in significantly increase in the levels of CGRP and SP in plasma and hearts, as well as the levels and mRNA expression of CGRP and SP in DRG. The increase in CGRP and SP levels in plasma and hearts were markedly inhibited by TRPV1 receptor antagonist capsazepine. These findings indicate that limb remote ischemic postconditioning could attenuate cardiac ischemia/reperfusion injury in rats, and the cardioprotective mechanism is via TRPV1-mediated upregulation of CGRP and SP, which could subsequently act on their corresponding receptors in heart tissue. (C) 2015 Elsevier Inc. All rights reserved.
机译:肢体远端缺血后处理(RIPostC)已被证明是安全有效的抗缺血再灌注损伤心脏保护措施。但是,桥接远端器官损伤和心脏心脏保护作用的方法仍有待阐明。这项研究旨在发现TRPV1是否可以介导从远端器官到心脏的心脏保护作用以及CGRP和SP在此过程中的作用。我们发现,RIPostC在限制梗死面积,降低CK和cTnI释放并改善心脏功能方面有效地改善了心脏缺血/再灌注损伤。此外,通过在再灌注前注射相应的拮抗剂(CGRP为CGRP8-37,SP为RP-67580)抑制CGRP或SP受体,可以显着消除这些心脏保护作用。此外,RIPostC导致血浆和心脏中CGRP和SP的水平显着增加,以及DRG中CGRP和SP的水平和mRNA表达。 TRPV1受体拮抗剂Capsazepine显着抑制了血浆和心脏中CGRP和SP水平的升高。这些发现表明,肢体远端缺血后处理可以减轻大鼠的心脏缺血/再灌注损伤,其心脏保护机制是通过TRPV1介导的CGRP和SP上调,其随后可能作用于心脏组织中的相应受体。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号